NCT02771093 (TRACK) is a Phase 4 clinical trial of Trelagliptin in Type 2 Diabetes Mellitus, sponsored by Takeda.

Who is sponsoring NCT02771093?

NCT02771093 is sponsored by Takeda.

What drugs are being tested in NCT02771093?

Interventions in NCT02771093: Trelagliptin, Alogliptin.

What condition does NCT02771093 study?

NCT02771093 studies Type 2 Diabetes Mellitus.

Is NCT02771093 still recruiting?

NCT02771093 is currently completed. Last updated 12 December 2023.

Are results published for NCT02771093?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-12-12 · How we verify

NCT02771093: TRACK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus

Completed Phase 4 Results posted Last updated 12 December 2023

What this trial tests

Phase 4 trial testing Trelagliptin in Type 2 Diabetes Mellitus in 27 participants. Completed in 27 April 2017.

Timeline

8 September 2016

Primary endpoint
27 April 2017

27 April 2017

Quick facts

Lead sponsor	Takeda
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	27
Start date	8 September 2016
Primary completion	27 April 2017
Estimated completion	27 April 2017
Sites	1 location across Japan

Drugs / interventions tested

Trelagliptin — full drug profile →
Alogliptin (ALOGLIPTIN) — full drug profile →

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →

Sponsor

Takeda — full company profile →

Who can join

20 and older, any sex, with Type 2 Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Changes From Baseline in the Standard Deviation (SD) of 24-hour Blood Glucose Values Primary · Baseline, up to 28 days

Changes in the SD of 24-hour blood glucose values (mg/dL) for each 7-day period between Week 3 and Week 4 (between Day 2 on Week 3 \[Day 22\] and Day 8 on Week 3 \[Day 28\]) of the treatment period, calculated from the value at the start of the observation period.

Day(D) 2 Week(W) 3

Group	Value	95% CI
Trelagliptin 100 mg	-7.51	-17.10 – 2.08
Alogliptin 25 mg	-13.04	-20.84 – -5.23

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-11.76	-21.12 – -2.40
Alogliptin 25 mg	-15.24	-21.87 – -8.61

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-11.71	-21.84 – -1.58
Alogliptin 25 mg	-12.91	-18.55 – -7.26

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-9.89	-19.83 – 0.05
Alogliptin 25 mg	-13.28	-21.28 – -5.27

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-12.75	-22.01 – -3.49
Alogliptin 25 mg	-11.94	-20.58 – -3.29

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-9.50	-18.58 – -0.42
Alogliptin 25 mg	-10.90	-20.00 – -1.80

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-7.35	-15.13 – 0.44
Alogliptin 25 mg	-11.63	-18.67 – -4.59

Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (180 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose when specific blood glucose levels (180 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.

D2W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-90.7	-559.9 – 378.5
Alogliptin 25 mg	-660.1	-1128.5 – -191.6

D3W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-241.2	-841.3 – 359.0
Alogliptin 25 mg	-592.9	-1016.9 – -169.0

D4W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-632.2	-1357.8 – 93.4
Alogliptin 25 mg	-375.6	-827.9 – 76.7

D5W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	36.5	-418.1 – 491.2
Alogliptin 25 mg	-776.3	-1602.1 – 49.6

D6W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-272.2	-673.5 – 129.0
Alogliptin 25 mg	-556.5	-1099.4 – -13.7

D7W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-264.2	-803.3 – 274.8
Alogliptin 25 mg	-578.2	-1000.6 – -155.8

D8W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-214.8	-639.5 – 209.8
Alogliptin 25 mg	-603.6	-1005.5 – -201.8

D2W3 after lunch

Group	Value	95% CI
Trelagliptin 100 mg	-300.3	-924.2 – 323.6
Alogliptin 25 mg	-626.6	-1126.4 – -126.7

Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (110 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose when specific blood glucose levels (110 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.

D2W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-203.7	-857.5 – 450.1
Alogliptin 25 mg	-1052.7	-1596.7 – -508.7

D3W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-662.6	-1590.9 – 265.7
Alogliptin 25 mg	-1030.9	-1538.5 – -523.4

D4W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-1024.6	-2341.3 – 292.1
Alogliptin 25 mg	-958.9	-1723.4 – -194.4

D5W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-97.2	-808.5 – 614.2
Alogliptin 25 mg	-1319.8	-2358.8 – -280.7

D6W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-696.1	-1333.9 – -58.3
Alogliptin 25 mg	-832.5	-1606.6 – -58.4

D7W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-573.8	-1309.2 – 161.5
Alogliptin 25 mg	-966.3	-1566.5 – -366.0

D8W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-399.0	-1034.8 – 236.8
Alogliptin 25 mg	-1024.8	-1550.4 – -499.2

D2W3 after lunch

Group	Value	95% CI
Trelagliptin 100 mg	-669.0	-1648.8 – 310.8
Alogliptin 25 mg	-1131.4	-1738.4 – -524.5

Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (140 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose when specific blood glucose levels (140 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.

D2W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-218.5	-811.5 – 374.4
Alogliptin 25 mg	-981.2	-1502.5 – -459.9

D3W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-510.2	-1377.6 – 357.2
Alogliptin 25 mg	-926.1	-1418.1 – -434.2

D4W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-886.4	-1860.8 – 88.0
Alogliptin 25 mg	-801.6	-1487.3 – -115.9

D5W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-21.3	-672.0 – 629.4
Alogliptin 25 mg	-1178.0	-2185.7 – -170.3

D6W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-559.8	-1140.7 – 21.0
Alogliptin 25 mg	-791.8	-1517.5 – -66.2

D7W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-457.4	-1154.7 – 239.9
Alogliptin 25 mg	-910.1	-1492.1 – -328.1

D8W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-348.5	-942.4 – 245.5
Alogliptin 25 mg	-951.6	-1450.0 – -453.1

D2W3 after lunch

Group	Value	95% CI
Trelagliptin 100 mg	-588.5	-1518.0 – 340.9
Alogliptin 25 mg	-1079.1	-1649.8 – -508.5

Change From Baseline in AUC for Blood Glucose When Specific Blood Glucose Levels (160 mg/dL) Are Observed During the 3 Hour Time Period After Breakfast, Lunch and Evening Meal Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose when specific blood glucose levels (160 mg/dL) were observed during the 3 hour time period after breakfast, lunch and evening meal at each time points was calculated.

D2W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-164.5	-704.0 – 374.9
Alogliptin 25 mg	-829.2	-1327.2 – -331.2

D3W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-377.8	-1142.0 – 386.4
Alogliptin 25 mg	-770.4	-1225.2 – -315.5

D4W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-759.4	-1568.6 – 49.8
Alogliptin 25 mg	-609.9	-1198.1 – -21.7

D5W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	25.6	-546.2 – 597.5
Alogliptin 25 mg	-981.3	-1918.9 – -43.6

D6W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-405.5	-912.4 – 101.5
Alogliptin 25 mg	-696.8	-1340.7 – -53.0

D7W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-356.6	-1001.3 – 288.0
Alogliptin 25 mg	-760.4	-1278.1 – -242.6

D8W3 after breakfast

Group	Value	95% CI
Trelagliptin 100 mg	-273.4	-787.3 – 240.5
Alogliptin 25 mg	-806.3	-1259.2 – -353.4

D2W3 after lunch

Group	Value	95% CI
Trelagliptin 100 mg	-448.1	-1249.4 – 353.2
Alogliptin 25 mg	-890.4	-1433.1 – -347.7

Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 140 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 140 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-1935.9	-4619.7 – 747.9
Alogliptin 25 mg	-4021.4	-5867.0 – -2175.7

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-2001.2	-4861.6 – 859.3
Alogliptin 25 mg	-3378.3	-6054.9 – -701.7

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-2978.2	-5095.6 – -860.8
Alogliptin 25 mg	-4119.9	-5855.8 – -2384.1

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-2981.5	-5010.4 – -952.5
Alogliptin 25 mg	-4230.4	-6524.2 – -1936.7

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-2550.5	-4308.5 – -792.4
Alogliptin 25 mg	-3840.0	-6136.0 – -1544.0

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-1946.5	-3589.5 – -303.5
Alogliptin 25 mg	-3566.4	-5763.1 – -1369.6

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-2043.5	-4237.3 – 150.4
Alogliptin 25 mg	-3667.1	-5489.4 – -1844.7

Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 160 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 160 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-1458.0	-3556.4 – 640.4
Alogliptin 25 mg	-3075.8	-4672.5 – -1479.1

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-1702.0	-3893.0 – 489.0
Alogliptin 25 mg	-2767.3	-4792.8 – -741.8

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-2335.8	-4011.2 – -660.3
Alogliptin 25 mg	-3273.0	-4820.1 – -1725.9

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-2171.8	-3923.9 – -419.8
Alogliptin 25 mg	-3384.5	-5073.8 – -1695.2

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-2031.0	-3588.9 – -473.1
Alogliptin 25 mg	-2990.8	-4843.0 – -1138.6

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-1636.5	-3081.2 – -191.9
Alogliptin 25 mg	-2768.9	-4705.6 – -832.1

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-1603.9	-3357.3 – 149.5
Alogliptin 25 mg	-2818.8	-4272.4 – -1365.2

Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels Reached 180 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose during periods when blood glucose levels reached 180 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-989.9	-2508.3 – 528.4
Alogliptin 25 mg	-2247.9	-3524.3 – -971.6

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-1332.7	-2948.0 – 282.6
Alogliptin 25 mg	-2086.7	-3524.9 – -648.5

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-1685.1	-3054.1 – -316.0
Alogliptin 25 mg	-2352.2	-3639.5 – -1065.0

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-1486.5	-2877.5 – -95.5
Alogliptin 25 mg	-2492.3	-3775.9 – -1208.6

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-1449.4	-2803.7 – -95.0
Alogliptin 25 mg	-2109.1	-3559.9 – -658.2

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-1264.2	-2516.7 – -11.8
Alogliptin 25 mg	-1976.3	-3590.5 – -362.1

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-1166.8	-2536.5 – 202.8
Alogliptin 25 mg	-2009.8	-3116.4 – -903.2

Change From Baseline in Time During Periods When Blood Glucose Levels Reached 140 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in cumulative time during periods when blood glucose levels reached 140 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-116.9	-321.9 – 88.1
Alogliptin 25 mg	-212.5	-326.5 – -98.5

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-105.0	-318.1 – 108.1
Alogliptin 25 mg	-147.1	-353.5 – 59.2

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-163.8	-338.4 – 10.8
Alogliptin 25 mg	-166.1	-312.4 – -19.8

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-192.3	-363.7 – -20.9
Alogliptin 25 mg	-163.2	-376.8 – 50.4

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-114.2	-300.0 – 71.5
Alogliptin 25 mg	-193.2	-370.9 – -15.6

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-96.9	-243.3 – 49.5
Alogliptin 25 mg	-182.1	-325.5 – -38.8

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-133.8	-328.2 – 60.5
Alogliptin 25 mg	-198.6	-348.0 – -49.2

Change From Baseline in Time During Periods When Blood Glucose Levels Reached 160 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in cumulative time during periods when blood glucose levels reached 160 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-134.2	-315.6 – 47.1
Alogliptin 25 mg	-229.3	-329.7 – -128.9

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-75.0	-291.9 – 141.9
Alogliptin 25 mg	-173.2	-356.0 – 9.6

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-167.7	-322.8 – -12.6
Alogliptin 25 mg	-234.3	-331.5 – -137.0

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-200.0	-323.0 – -77.0
Alogliptin 25 mg	-236.8	-389.3 – -84.2

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-153.1	-287.4 – -18.7
Alogliptin 25 mg	-232.9	-361.4 – -104.3

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-93.5	-209.1 – 22.1
Alogliptin 25 mg	-213.2	-328.9 – -97.5

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-115.0	-255.6 – 25.6
Alogliptin 25 mg	-225.4	-339.3 – -111.4

Change From Baseline in Time During Periods When Blood Glucose Levels Reached 180 mg/dL (Hyperglycemia) Secondary · Baseline, up to 28 days

Change from baseline in cumulative time during periods when blood glucose levels reached 180 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-91.2	-255.3 – 73.0
Alogliptin 25 mg	-210.7	-315.9 – -105.6

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-117.3	-271.7 – 37.1
Alogliptin 25 mg	-167.1	-324.6 – -9.7

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-167.3	-262.0 – -72.6
Alogliptin 25 mg	-236.4	-339.0 – -133.8

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-153.1	-273.6 – -32.6
Alogliptin 25 mg	-225.4	-341.4 – -109.4

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-137.7	-234.0 – -41.4
Alogliptin 25 mg	-216.8	-336.1 – -97.5

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-94.2	-185.2 – -3.2
Alogliptin 25 mg	-194.3	-308.5 – -80.1

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-105.0	-232.7 – 22.7
Alogliptin 25 mg	-193.2	-290.5 – -96.0

Change From Baseline in AUC for Blood Glucose During Periods When Blood Glucose Levels is Less Than 70 mg/dL (Hypoglycemia) Secondary · Baseline, up to 28 days

Change from baseline in AUC for blood glucose during periods when blood glucose levels was less than 70 mg/dL at each time points was calculated.

D2W3

Group	Value	95% CI
Trelagliptin 100 mg	-31.2	-105.8 – 43.3
Alogliptin 25 mg	0.4	-0.4 – 1.1

D3W3

Group	Value	95% CI
Trelagliptin 100 mg	-43.0	-136.3 – 50.3
Alogliptin 25 mg	0.0	0.0 – 0.0

D4W3

Group	Value	95% CI
Trelagliptin 100 mg	-42.3	-135.8 – 51.2
Alogliptin 25 mg	13.4	-14.0 – 40.8

D5W3

Group	Value	95% CI
Trelagliptin 100 mg	-30.5	-129.9 – 68.8
Alogliptin 25 mg	26.9	-8.9 – 62.6

D6W3

Group	Value	95% CI
Trelagliptin 100 mg	-39.8	-134.0 – 54.3
Alogliptin 25 mg	0.0	0.0 – 0.0

D7W3

Group	Value	95% CI
Trelagliptin 100 mg	-43.0	-136.3 – 50.3
Alogliptin 25 mg	0.0	0.0 – 0.0

D8W3

Group	Value	95% CI
Trelagliptin 100 mg	-43.0	-136.3 – 50.3
Alogliptin 25 mg	0.0	0.0 – 0.0

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 29 days. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Alogliptin 25 mg

Serious: 0/13 (0%)

Deaths: 0/13

Trelagliptin 100 mg

Serious: 0/14 (0%)

Deaths: 0/14

Other adverse events (5 terms — click to expand)

Reaction	System	Alogliptin 25 mg	Trelagliptin 100 mg
Gastric mucosal lesion	Gastrointestinal disorders	—	—
Feeling abnormal	General disorders	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—
Dizziness	Nervous system disorders	—	—
Eczema	Skin and subcutaneous tissue disorders	—	—

Data from ClinicalTrials.gov NCT02771093 adverse events section.

Sponsor's own description

This is a multi-center, randomized, open-label, parallel-group comparative, exploratory study to evaluate the effect of trelagliptin administered at a dose of 100 mg once weekly or alogliptin administered at a dose of 25 mg once daily for 4 weeks on glycemic variation in patients with type 2 diabetes mellitus using continuous glucose monitoring (CGM).

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Signaling pathways and intervention for therapy of type 2 diabetes mellitus.
Cao R, Tian H, Zhang Y, Liu G, et al · · 2023 · cited 30× · PMID 37303813 · DOI 10.1002/mco2.283
A Randomized Pilot Study of the Effect of Trelagliptin and Alogliptin on Glycemic Variability in Patients with Type 2 Diabetes.
Nishimura R, Osonoi T, Koike Y, Miyata K, et al · · 2019 · cited 13× · PMID 31562608 · DOI 10.1007/s12325-019-01097-z

Verify or expand the search:

Other trials of Trelagliptin

Trials testing the same drug.

NCT04285983 — Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Sev · completed
NCT04374864 — Dose Modification Requirement for Trelagliptin in Egyptian Population · Phase 4 · unknown
NCT03231709 — Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants · Phase 4 · completed
NCT03014479 — Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus · Phase 4 · completed
NCT03555591 — Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus" · completed

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02771093 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 12 December 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02771093.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02771093: TRACK

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Trelagliptin

Other recruiting trials for Type 2 Diabetes Mellitus

Other Takeda trials

Verify against primary sources